Results 1 to 10 of about 820 (140)
Emicizumab in children: bleeding episodes and outcome before and after transition to Emicizumab
BMC Pediatrics, 2022 Purpose Real-world data and study data regarding therapy with Emicizumab in pediatric cohorts with haemophilia A is scarce. Especially, data on previously untreated pediatric patients (PUPs) and minimally treated patients (MTPs) are missing.
Hannah Glonnegger +5 more
doaj +5 more sources
No correlation between thrombin generation and emicizumab levels: implications for monitoring emicizumab therapy [PDF]
Research and Practice in Thrombosis and HaemostasisBackground: Emicizumab, a bispecific antibody that mimics factor (F)VIII, has significantly improved hemophilia A management. Although emicizumab levels can be measured, tools for estimating the hemostatic efficacy of emicizumab are lacking.
Konrad van der Zwet +6 more
doaj +5 more sources
Emicizumab-induced photosensitivity
TH Open, 2022 Emicizumab constitutes a novel and effective prophylaxis for hemophilia A patients with and without inhibitors. In this case report, we describe an emicizumab-induced photosensitivity that forced permanent sun-exposure suppression.
Pedro Asensi Cantó +6 more
doaj +4 more sources
Quantification of emicizumab by mass spectrometry in plasma of people with hemophilia A: A method validation study [PDF]
Research and Practice in Thrombosis and Haemostasis, 2022 Background Emicizumab is a new treatment option for people with hemophilia A. Emicizumab was approved with a body‐weight‐based dosage regimen, without laboratory monitoring requirements.
Anouk A M T Donners +1 more
exaly +3 more sources
The effect of emicizumab and bypassing agents in patients with hemophilia – An in vitro study
Research and Practice in Thrombosis and Haemostasis, 2021 Background Emicizumab is a nonfactor replacement therapy for hemophilia A (HA) and is a bispecific monoclonal antibody mimicking factor VIII by binding both factors IXa and X.
Nina Haagenrud Schultz +3 more
doaj +2 more sources
Influence of emicizumab on protein C-mediated clotting regulation
Bleeding, Thrombosis and Vascular Biology, 2023 Emicizumab, a FVIII-mimetic bispecific antibody, is insensitive to degradation by activated protein C (APC) and may thus induce a procoagulant state. We investigated the effect of emicizumab on protein C-mediated inhibition of coagulation under in vitro
Federica Mancazzo +5 more
doaj +2 more sources
Emicizumab state‐of‐the‐art update
Haemophilia, 2022 AbstractIntroductionEmicizumab is a bispecific monoclonal antibody developed to address the unmet needs of clotting factor replacement therapy and has become the benchmark for optimal prophylaxis in managing patients with haemophilia A with inhibitors.
Johnny Mahlangu +2 more
exaly +4 more sources
Hematology, Transfusion and Cell Therapy, 2023 Aim: Valoctocogene roxaparvovec (AAV5-hFVIII-SQ) is a gene therapy evaluated in the phase 3 GENEr8-1 trial that provides endogenous factor VIII (FVIII) production to prevent bleeding in people with severe hemophilia A and represents an alternative to ...
W Kuwabara +9 more
doaj +1 more source
Haematologica, 2023 Recombinant factor VIII (rFVIII), rFVIIIFc and emicizumab are established treatment options in the management of hemophilia A. Each has its unique mode of action, which can influence thrombin generation kinetics and therefore also the kinetics of ...
Thibaud Sefiane +9 more
doaj +1 more source
Research and Practice in Thrombosis and Haemostasis, 2021 Background Emicizumab, a bispecific antibody factor VIII mimetic, is approved for prophylaxis in hemophilia, and has different risks and side effects compared to factor VIII products.
Beth Boulden Warren +9 more
doaj +1 more source